Sage Therapeutics, Inc. (SAGE)
NasdaqGM - NasdaqGM Real-time price. Currency in USD
Add to watchlist
As of 12:01PM EDT. Market open.
| Previous close | 14.18 |
| Open | 13.95 |
| Bid | 14.06 x 100 |
| Ask | 14.14 x 300 |
| Day's range | 13.90 - 14.48 |
| 52-week range | 10.92 - 59.99 |
| Volume | |
| Avg. volume | 1,057,254 |
| Market cap | 848.566M |
| Beta (5Y monthly) | 0.85 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -8.39 |
| Earnings date | 25 Apr 2024 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | 21.88 |
Simply Wall St.Earnings Update: Sage Therapeutics, Inc. (NASDAQ:SAGE) Just Reported And Analysts Are Boosting Their Estimates
Investors in Sage Therapeutics, Inc. ( NASDAQ:SAGE ) had a good week, as its shares rose 2.7% to close at US$13.69...
ZacksSage Therapeutics (SAGE) Q1 Earnings Miss, Sales Beat Estimates
Sage Therapeutics' (SAGE) first-quarter 2024 results are mixed as earnings miss estimates, but sales beat the mark. The newly-launched depression drug Zurzuvae drives the company's top line.
Simply Wall St.Sage Therapeutics First Quarter 2024 Earnings: Revenues Beat Expectations, EPS Lags
Sage Therapeutics ( NASDAQ:SAGE ) First Quarter 2024 Results Key Financial Results Revenue: US$7.90m (up 140% from 1Q...
© 2024 Yahoo. All rights reserved.